Skip to content
DoMore Diagnostics logo — Personalized medicine made simple with artificial intelligen...

DoMore Diagnostics

Personalized medicine made simple with artificial intelligence

Founded 2021 Norway Norway 14 employees Total: $5.50M

General Information

Company Name DoMore Diagnostics
Founded Year 2021
Location Norway Norway
Employees 14
Business Model B2B, SaaS, B2B2C
Revenue Model Usage Based, Service Fee, Subscription
Social

BounceWatch is an independent company data service, not affiliated with DoMore Diagnostics. To contact DoMore Diagnostics, visit domorediagnostics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does DoMore Diagnostics compare?

A PDF of DoMore Diagnostics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting DoMore Diagnostics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Oct 22, 2026

DoMore Diagnostics will present clinical validation study results for Histotype Px® Colorectal at ESMO 2026 in Madrid.

About DoMore Diagnostics

DoMore Diagnostics, founded in 2021, is transforming personalized medicine through its innovative use of artificial intelligence. The startup’s slogan, "Personalized medicine made simple with artificial intelligence", encapsulates its mission to democratize access to precise cancer treatment.

Its flagship product, Histotype Px® Colorectal, is a CE-IVDD marked digital biomarker. It’s specifically designed for stage II and III colorectal adenocarcinoma, providing critical support in deciding whether adjuvant chemotherapy is needed post-surgery. This AI-driven tool enhances the role of pathologists, integrating smoothly into existing workflows to improve patient outcomes.

Supported by leading international research and backed by prominent Norwegian tech investors, DoMore Diagnostics stands at the forefront of medical innovation. Its technology, focused on accessibility and integration, positions it as a noteworthy contender in the personalized medicine landscape.

Business keywords: Personalized Medicine, Cancer Treatment, Digital Biomarkers, Tumor Tissue Analysis, Pathology Workflow Integration, Colorectal Cancer, Outcome Prediction, Adjuvant Chemotherapy Decision, Deep Learning, Prognostication, CE-IVDD Marked Products, Precision Medicine, Digital Diagnostics

Services & Products

Personalized cancer treatment solutions
AI-driven diagnostic methods
Digital biomarker development
Cancer prognosis improvement

Target Customers

Cancer patients Healthcare providers Clinical researchers Medical institutions

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Angel €1.80M 2
Norselab, Silversky
01 Aug 2024
Grant $2.50M 1
European Innovation Council
01 Nov 2023
Angel €1.20M 2
Norselab, Grotmol Solutions
01 Jun 2021
Support Program Undisclosed 2
University Ventures, University of Oslo
01 Sep 2020

DoMore Diagnostics Alternatives & Competitors

DoMore Diagnostics vs

Pioneering Precision Medicine

Grant
7 employees
Biopharma, Biotechnology
DoMore Diagnostics vs
Panakeia
Panakeia United Kingdom

Rapid, instrument-free precision cancer diagnostics

23 employees
DoMore Diagnostics vs

Data & Biomarker Performance Analysis; Artificial Intelligence; Software Development.

2 employees
Biotechnology, Life Sciences

FAQ About DoMore Diagnostics

Personalized medicine made simple with artificial intelligence
DoMore Diagnostics was founded in 2021.
DoMore Diagnostics is headquartered in Norway.
DoMore Diagnostics has a B2B, SaaS and B2B2C business model. Its revenue comes from Usage Based, Service Fee and Subscription.
DoMore Diagnostics has approximately 14 employees.
DoMore Diagnostics has completed 4 funding rounds, raising a total of $5.50M.
DoMore Diagnostics offers: Personalized cancer treatment solutions, AI-driven diagnostic methods, Digital biomarker development, Cancer prognosis improvement.
Top alternatives and competitors to DoMore Diagnostics include Oxford Cancer Biomarkers, Panakeia, AnaBioSi-Data Ltd, Exact Sciences, PathAI. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DoMore Diagnostics and Oxford Cancer Biomarkers are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for DoMore Diagnostics, https://bouncewatch.com/company/domore-diagnostics, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout